JP2024547001A5 - - Google Patents
Info
- Publication number
- JP2024547001A5 JP2024547001A5 JP2024536189A JP2024536189A JP2024547001A5 JP 2024547001 A5 JP2024547001 A5 JP 2024547001A5 JP 2024536189 A JP2024536189 A JP 2024536189A JP 2024536189 A JP2024536189 A JP 2024536189A JP 2024547001 A5 JP2024547001 A5 JP 2024547001A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- pharmaceutical composition
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291315P | 2021-12-17 | 2021-12-17 | |
| US63/291,315 | 2021-12-17 | ||
| IBPCT/IB2021/000937 | 2021-12-17 | ||
| PCT/IB2021/000937 WO2023111618A1 (en) | 2021-12-17 | 2021-12-17 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| PCT/US2022/079509 WO2023114586A1 (en) | 2021-12-17 | 2022-11-08 | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024547001A JP2024547001A (ja) | 2024-12-26 |
| JP2024547001A5 true JP2024547001A5 (https=) | 2025-12-19 |
Family
ID=84387973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536189A Pending JP2024547001A (ja) | 2021-12-17 | 2022-11-08 | 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250051427A1 (https=) |
| EP (1) | EP4448005A1 (https=) |
| JP (1) | JP2024547001A (https=) |
| KR (1) | KR20240115910A (https=) |
| AU (1) | AU2022410770A1 (https=) |
| CA (1) | CA3242280A1 (https=) |
| MX (1) | MX2024007288A (https=) |
| WO (1) | WO2023114586A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025019457A1 (en) | 2023-07-15 | 2025-01-23 | Eisai R&D Management Co., Ltd. | Antimicrobial peptides |
| WO2025049938A1 (en) * | 2023-08-31 | 2025-03-06 | Florida Atlantic University Board Of Trustees | Non-invasive delivery method of antibodies to the brain for treatment of brain diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210324056A1 (en) * | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN112187401B (zh) | 2019-07-03 | 2022-06-14 | 华为技术有限公司 | 多时间单元传输方法及相关装置 |
| US11877315B2 (en) | 2020-09-15 | 2024-01-16 | Qualcomm Incorporated | Wireless device digital beamforming capability indication |
-
2022
- 2022-11-08 MX MX2024007288A patent/MX2024007288A/es unknown
- 2022-11-08 CA CA3242280A patent/CA3242280A1/en active Pending
- 2022-11-08 EP EP22817858.8A patent/EP4448005A1/en active Pending
- 2022-11-08 AU AU2022410770A patent/AU2022410770A1/en active Pending
- 2022-11-08 WO PCT/US2022/079509 patent/WO2023114586A1/en not_active Ceased
- 2022-11-08 US US18/720,518 patent/US20250051427A1/en active Pending
- 2022-11-08 KR KR1020247023419A patent/KR20240115910A/ko active Pending
- 2022-11-08 JP JP2024536189A patent/JP2024547001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mallah et al. | Anti-inflammatory and neuroprotective agents in clinical trials for CNS disease and injury: where do we go from here? | |
| Godyń et al. | Therapeutic strategies for Alzheimer's disease in clinical trials | |
| Sun et al. | Review of drugs for Alzheimer's disease | |
| Gandy et al. | Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress | |
| JP2024547001A5 (https=) | ||
| JP2024112859A5 (https=) | ||
| JP5349297B2 (ja) | ペプチド免疫応答増強方法 | |
| JP2014114288A5 (https=) | ||
| Wang et al. | Lessons from anti-amyloid-β immunotherapies in alzheimer disease: Aiming at a moving target | |
| DK2758061T3 (en) | COMBINATION OF ANTIBIOTICS FOR TREATING AN AUTO-IMMUNE DISORDER | |
| JP2018530574A5 (https=) | ||
| JP2023527542A5 (https=) | ||
| Dai et al. | Amyloid-beta targeted therapeutic approaches for Alzheimer’s disease: long road ahead | |
| JP2019519584A5 (https=) | ||
| JP2023513220A5 (https=) | ||
| Luca et al. | A Phase 1 single-ascending-dose trial in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of intravenous pnt001, a novel mid-domain tau antibody targeting cis-pT231 tau | |
| WO2013017053A1 (zh) | 一种防治老年痴呆症复合疫苗及其制备方法 | |
| Narang et al. | Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single‐centre pilot study. | |
| ES3006014T3 (en) | Use of nalfurafine for the treatment of demyelinating diseases | |
| Mascarella et al. | The ultimate guide to the anti-CGRP monoclonal antibodies galaxy | |
| Vijayakumar et al. | Slowing Parkinson’s disease progression with vaccination and other immunotherapies | |
| JP2024532438A5 (https=) | ||
| JP2024540294A5 (https=) | ||
| AU2020266279A1 (en) | Rebamipide for use in prevention and/or treatment of synucleinopathies | |
| Yeung et al. | Use of steroids for erythema multiforme in children. |